-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 22, 2022, Janssen China signed a strategic cooperation memorandum of understanding with the National Center for Infectious Diseases (relying on Huashan Hospital Affiliated to Fudan University, referred to as the "National Center") and Shanghai Huashen Institute of Microbiology and Infection (referred to as the "MOU").
”)
.
All parties will carry out strategic cooperation in the dimensions of scientific research, technology development, industrial transformation and academic exchanges, aiming to promote the sustainable development of the field of anti-infection, improve the level of public health, and contribute to the construction of "Healthy China 2030"
.
The "14th Five-Year Plan" clearly pointed out that the focus of adjusting the medical and health system should be shifted to the field of public health
.
As one of the core disease areas of public health, the prevention and control of infectious diseases is of great significance to improving China's public health level
.
Professor Zhang Wenhong, director of the National Center, said, "At present, the diagnosis, treatment and prevention of infectious diseases in China are still facing severe challenges.
The signing of this memorandum will deepen the in-depth cooperation between the National Center and Yang Sen, and the cooperation results will help clinicians to improve
Zheng Lei, President of Janssen China, said: “As a transformative and innovative medical company, and the earliest multinational pharmaceutical company deeply rooted in China One, Janssen China has always actively promoted the in-depth integration and innovation of industrial ecology to promote the development of public health
.
The signing of this memorandum will focus on patient-centered integrated solutions for diagnosis and treatment, and create a win-win anti-infection The ecosystem is another important commitment we have made to help China's public health
.
" According to the memorandum, Janssen China and the National Center will work with multiple partners to build a patient-centered integrated diagnosis and treatment for the full path of disease discovery, diagnosis, and treatment.
platform to create a win-win anti-infection ecosystem to achieve a new pattern of infectious disease prevention and control
.
Taking MDR-TB as an example, a patient-centered ecosystem will build a full-cycle management of MDR-TB screening, identification, referral, treatment, and follow-up by integrating government agencies and multi-industry partners.
Standardized treatment system and referral mechanism for multidrug pulmonary tuberculosis, bringing greater benefits to patients
.
The construction of this anti-infective ecosystem will not only help patients achieve early diagnosis and treatment, and obtain more optimized whole-process disease management, but also improve the diagnosis and treatment level of grass-roots medical staff, help the comprehensive development of anti-infective disciplines, and increase mutual cooperation between all parties in the industry.
Opportunities for dialogue, promote diverse exchanges and cooperation in the field of anti-infection, and promote the deep integration and innovation of industrial ecology
.
In addition, Janssen will also have discussions and exchanges with the National Center on international cooperation in early scientific research, innovation incubation, clinical research, and medical translation, and explore new technologies in multidrug-resistant tuberculosis, hepatitis, respiratory syncytial virus, and extraintestinal pathogenic Escherichia coli.
Potential cooperation directions in areas such as bacterial infection
.
As a witness and participant in the development and progress of China's public health undertakings, Janssen China has long been deeply involved in the field of multi-drug-resistant tuberculosis, hepatitis, AIDS and other anti-infective diseases, and has accumulated rich practical experience
.
Under the guidance of the policy-based, partner-based and intelligent public health strategy, Janssen China is committed to advocating a positive policy environment, exploring innovative cooperation models to link multiple partners, and using intelligent platforms to enhance public awareness through digital education Disease popularization and training of talents in the medical field
.
”)
.
All parties will carry out strategic cooperation in the dimensions of scientific research, technology development, industrial transformation and academic exchanges, aiming to promote the sustainable development of the field of anti-infection, improve the level of public health, and contribute to the construction of "Healthy China 2030"
.
The "14th Five-Year Plan" clearly pointed out that the focus of adjusting the medical and health system should be shifted to the field of public health
.
As one of the core disease areas of public health, the prevention and control of infectious diseases is of great significance to improving China's public health level
.
Professor Zhang Wenhong, director of the National Center, said, "At present, the diagnosis, treatment and prevention of infectious diseases in China are still facing severe challenges.
The signing of this memorandum will deepen the in-depth cooperation between the National Center and Yang Sen, and the cooperation results will help clinicians to improve
Zheng Lei, President of Janssen China, said: “As a transformative and innovative medical company, and the earliest multinational pharmaceutical company deeply rooted in China One, Janssen China has always actively promoted the in-depth integration and innovation of industrial ecology to promote the development of public health
.
The signing of this memorandum will focus on patient-centered integrated solutions for diagnosis and treatment, and create a win-win anti-infection The ecosystem is another important commitment we have made to help China's public health
.
" According to the memorandum, Janssen China and the National Center will work with multiple partners to build a patient-centered integrated diagnosis and treatment for the full path of disease discovery, diagnosis, and treatment.
platform to create a win-win anti-infection ecosystem to achieve a new pattern of infectious disease prevention and control
.
Taking MDR-TB as an example, a patient-centered ecosystem will build a full-cycle management of MDR-TB screening, identification, referral, treatment, and follow-up by integrating government agencies and multi-industry partners.
Standardized treatment system and referral mechanism for multidrug pulmonary tuberculosis, bringing greater benefits to patients
.
The construction of this anti-infective ecosystem will not only help patients achieve early diagnosis and treatment, and obtain more optimized whole-process disease management, but also improve the diagnosis and treatment level of grass-roots medical staff, help the comprehensive development of anti-infective disciplines, and increase mutual cooperation between all parties in the industry.
Opportunities for dialogue, promote diverse exchanges and cooperation in the field of anti-infection, and promote the deep integration and innovation of industrial ecology
.
In addition, Janssen will also have discussions and exchanges with the National Center on international cooperation in early scientific research, innovation incubation, clinical research, and medical translation, and explore new technologies in multidrug-resistant tuberculosis, hepatitis, respiratory syncytial virus, and extraintestinal pathogenic Escherichia coli.
Potential cooperation directions in areas such as bacterial infection
.
As a witness and participant in the development and progress of China's public health undertakings, Janssen China has long been deeply involved in the field of multi-drug-resistant tuberculosis, hepatitis, AIDS and other anti-infective diseases, and has accumulated rich practical experience
.
Under the guidance of the policy-based, partner-based and intelligent public health strategy, Janssen China is committed to advocating a positive policy environment, exploring innovative cooperation models to link multiple partners, and using intelligent platforms to enhance public awareness through digital education Disease popularization and training of talents in the medical field
.
